Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NYSEAMERICAN:CATX

Perspective Therapeutics Q3 2025 Earnings Report

Perspective Therapeutics logo
$2.52 +0.02 (+0.80%)
Closing price 04:10 PM Eastern
Extended Trading
$2.56 +0.04 (+1.79%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Perspective Therapeutics EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.33
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Perspective Therapeutics Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.21 million
Beat/Miss
Beat by +$2.00 thousand
YoY Revenue Growth
N/A

Perspective Therapeutics Announcement Details

Quarter
Q3 2025
Date
11/10/2025
Time
After Market Closes
Conference Call Date
Monday, November 10, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Perspective Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Perspective Therapeutics' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Perspective Therapeutics' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Perspective Therapeutics Earnings Headlines

Wedbush Reiterates Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)
September 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31027862
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)
September 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SRPT/pressreleases/4632298/analysts-conflicted-on-these-healthcare-names-sarepta-therapeutics-srpt-addus-homecare-adus-and-perspective-therapeutics-catx/
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
September 25 at 1:00 AM  |  Base Camp Trading (Ad)
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α ...
September 14, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pb-psv359-in-combination-with-keytruda-pembrolizumab-in-fap--positive-solid-tumors-1036542439
Perspective Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate PSV359 in Combination with Keytruda in Advanced FAP-α-Positive Solid Tumors
September 14, 2026  |  quiverquant.comQ
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3360885/0/en/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pb-psv359-in-combination-with-keytruda-pembrolizumab-in-fap-%ce%b1-positive-soli.html
See More Perspective Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Perspective Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perspective Therapeutics and other key companies, straight to your email.

About Perspective Therapeutics

Perspective Therapeutics (NYSEAMERICAN:CATX) is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue.

Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals. Its pipeline has included VMT01, a targeted alpha therapy being studied for patients with metastatic melanoma, and VMT-α-NET, a program designed to target somatostatin receptor-positive neuroendocrine tumors. These programs are being evaluated in clinical studies to assess their safety, targeting capabilities and potential therapeutic benefits.

The company is headquartered in Seattle, Washington, and is developing the infrastructure and manufacturing capabilities needed to support radiopharmaceutical production and clinical development. Perspective Therapeutics serves the oncology market through its research and development activities, with a focus on cancers that can be identified through molecular targets and treated using targeted alpha-particle therapy.

View Perspective Therapeutics Profile
Earnings Tools